147 related articles for article (PubMed ID: 2869027)
1. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
Manos N; Lavrentiadis G; Gkiouzepas J
J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic medication and the elderly.
Raskin DE
J Clin Psychiatry; 1985 May; 46(5 Pt 2):36-40. PubMed ID: 2859280
[TBL] [Abstract][Full Text] [Related]
3. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Sramek JJ; Simpson GM; Morrison RL; Heiser JF
J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.
Murphy JE; Stewart RB
Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755
[TBL] [Abstract][Full Text] [Related]
5. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
Bermanzohn PC; Siris SG
J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
[TBL] [Abstract][Full Text] [Related]
6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
7. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
Miodownik C; Cohen H; Kotler M; Lerner V
Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
[TBL] [Abstract][Full Text] [Related]
8. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Cesková E; Svestka J
Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
[TBL] [Abstract][Full Text] [Related]
12. Rapid tranquilization: a comparison of thiothixene with loxapine.
Dubin WR; Weiss KJ
J Clin Psychiatry; 1986 Jun; 47(6):294-7. PubMed ID: 3711026
[TBL] [Abstract][Full Text] [Related]
13. Use or abuse of antiparkinsonian drugs by psychiatric patients.
Saran AS
J Clin Psychiatry; 1986 Mar; 47(3):130-2. PubMed ID: 2869028
[TBL] [Abstract][Full Text] [Related]
14. Clozapine in severe mood disorders.
Zarate CA; Tohen M; Baldessarini RJ
J Clin Psychiatry; 1995 Sep; 56(9):411-7. PubMed ID: 7665540
[TBL] [Abstract][Full Text] [Related]
15. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
[TBL] [Abstract][Full Text] [Related]
16. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
17. A double-blind comparison of the efficacy of EX 10-029 and trihexyphenidyl hydrochloride in relieving drug-induced Parkinsonian symptoms.
Freeman H; Mehta IS
Curr Ther Res Clin Exp; 1972 Aug; 14(8):470-7. PubMed ID: 4629309
[No Abstract] [Full Text] [Related]
18. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders.
Jónsdóttir H; Friis S; Horne R; Pettersen KI; Reikvam A; Andreassen OA
Acta Psychiatr Scand; 2009 Jan; 119(1):78-84. PubMed ID: 18983630
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study.
Horiguchi J; Nishimatsu O
Jpn J Psychiatry Neurol; 1992 Sep; 46(3):733-9. PubMed ID: 1362592
[TBL] [Abstract][Full Text] [Related]
20. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.
Nothdurfter C; Eser D; Schüle C; Zwanzger P; Marcuse A; Noack I; Möller HJ; Rupprecht R; Baghai TC
World J Biol Psychiatry; 2006; 7(3):162-70. PubMed ID: 16861142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
